Recipharm Advanced Bio
Stockholm, Sweden
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
63.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (11)
○ EMA GMP
○ MHRA GMP
Quick Facts: Recipharm Advanced Bio
- Signal Score
- 63.0/100 (as of 2026-09-07)
- Quality Compliance
- Assessment pending
- Headquarters
- Stockholm, Sweden
- Modalities
- AAV, Lentiviral, Cell Therapy
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Recipharm Advanced Bio
Pure-play CDMO.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Cell Therapy
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
68.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
58.0
Profile-based capacity assessment
Recent Press11 articles
Recent News 11 articles
Recipharm shutters Boxborough facility, cuts local workforce 40% - Worcester Business Journal
Recipharm shutters Boxborough facility, cuts local workforce 40% Worcester Business Journal
Change at the top at Recipharm as strategy shifts - pharmaphorum
Recipharm focuses footprint with sale of Israel API plant, new CDMO partnership - Fierce Pharma
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration - PR Newswire
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm - PR Newswire
Recipharm makes major investment to expand US sterile manufacturing footprint - European Pharmaceutical Review
Recipharm channels ‘multi-million-dollar' US manufacturing upgrade, targeting domestic biologics demand - Fierce Pharma
Recipharm and Exela Pharma Sciences Form Exclusive CDMO Strategic Alliance - Genetic Engineering and Biotechnology News
Recipharm bolsters fill/finish capacity at German site - BioProcess International
LGC opens $72M chemical plant; Recipharm partners with NeuroSense - Endpoints News
Responding to tougher FDA standards, Recipharm debuts new facility for beta-lactam drugs - Fierce Pharma
Frequently Asked Questions About Recipharm Advanced Bio
What is Recipharm Advanced Bio's CDMO Signal Score?
Recipharm Advanced Bio has a Signal Score of 63/100, based on quality, operations, financial stability, and capacity data.
Evaluating Recipharm Advanced Bio for a manufacturing program?
Use the free AI matchmaker to compare Recipharm Advanced Bio against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
OmniaBio
Hamilton, ON
Signal Score: 79.5
AAV, Lentiviral, CAR-T, Cell Therapy
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
Signal Score: 79.5
Viral Vectors, AAV, Lentiviral, Adenoviral, HPAPIs, Small Molecules, Peptides, BioCatalysis, Chromatography, Cell Therapy
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 78.6
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein
NecstGen
Leiden, NL
Signal Score: 78.1
AAV, Lentiviral, Cell Therapy